Acoramidis cuts clinical worsening 34% versus tafamidis in real-world ATTR-CM study
AI Summary- BridgeBio reported acoramidis had lower clinical worsening risk than tafamidis in ATTR-CM patients.
- Acoramidis reduced composite worsening risk 34% and diuretic intensification risk 43%.
- The claims analysis followed 618 newly treated individuals for approximately 4.6 months.